Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide

Implications for the Treatment of Low-Grade Adult and Pediatric Brain Tumors

William J. Bodell, Nilesh W. Gaikwad, Douglas Miller and Mitchel S. Berger
William J. Bodell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nilesh W. Gaikwad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchel S. Berger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors. Treatment of patients with alkylating chemotherapeutic agents has been established to increase their risk for acute myelogenous leukemia. The formation of DNA adducts and induction of mutations are likely to play a role in the etiology of therapy-related acute myeloid leukemia. To evaluate this issue for TMZ, we have measured the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. Treatment of Big Blue Rat-2 cells with either 0, 0.5, or 1 mm TMZ resulted in lacI mutant frequencies of 9.1 ± 2.9 × 10−5, 48.9 ± 12 × 10−5, and 89.7 ± 40.3 × 10−5, respectively. Comparison of the mutant frequencies demonstrated that 0.5 and 1 mm TMZ treatments increased the mutant frequencies by 5.3- and 9.8-fold and that this increase was significant (P < 0.001). Sequence analysis of the lacI mutants from the TMZ treatment group demonstrated that they were GC→AT transitions at non-CpG sites, which is significantly different from the mutation spectrum observed in the control treatment group. Treatment of Big Blue Rat-2 cells with various concentrations of TMZ produced a linear increase in the levels of N7-methylguanine and O6-methylguanine. The lacI mutation spectrum induced by TMZ treatment is consistent with these mutations being produced by O6-MeG. This study establishes TMZ has significant mutagenic potential and suggests that careful consideration in the use of TMZ for the treatment of low-grade adult and pediatric brain tumors should be given.

Introduction

Each year, ∼14,000 patients are diagnosed with primary brain tumors. Approximately 85% of these tumors are classified as GBM.3 Despite aggressive therapy, the survival of patients with GBM tumors remains 12–18 months. As a consequence of this poor survival, there is a continuous search for new agents and combinations of agents to improve the therapeutic response of GBM tumors. Recently, a new agent, TMZ, developed by Malcolm Stevens has been approved for treatment of anaplastic gliomas (1 , 2) . In clinical trials, p.o. administration of TMZ has demonstrated therapeutic activity in the treatment of GBM tumors, anaplastic astrocytomas, and oligodendrogliomas (3, 4, 5, 6, 7, 8) . Because of this activity, TMZ is being evaluated at a number of centers both as a single agent and in combination with other agents for the treatment of adult and pediatric brain tumors (9, 10, 11) .

Although TMZ is a new agent, it falls within a group of well-characterized methylating chemotherapeutic agents, which include PCB, DTIC, and STZ (Fig. 1)⇓ . These agents after either P450 oxidation or chemical hydrolysis generate a methylating agent that reacts with genomic DNA to form adducts (12, 13, 14, 15, 16, 17, 18, 19) . Although these DNA adducts are not directly cytotoxic, their presence in nuclear DNA initiates a cascade of events which ultimately results in cellular death (20 , 21) . In addition to their therapeutic properties, these agents have been demonstrated to be mutagenic (22, 23, 24, 25) and carcinogenic (26, 27, 28) .

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Structures of the chemotherapeutic agents TMZ, DTIC, PCB, and STZ.

It has been recognized that treatment of patients with alkylating chemotherapeutic agents results in a significant increase in risk for therapy-related leukemias and preleukemias, including t-AML and t-MDS (29 , 30) . Although the observation of t-AML and t-MDS in adult brain tumor patients treated with alkylating chemotherapeutic agents is rare (31, 32, 33) , we believe that this is because of the short life span of patients with GBM tumors who make up the majority of patients rather than lack of the process. The survival of patients with GBM tumors is from 12 to 18 months with <5% of the patients surviving 5 years (34) , whereas the appearance of t-AML or t-MDS usually occurs 3–5 years after treatment (29, 30, 31, 32, 33) . These facts indicate that most patients with GBM tumors have died before either t-AML or t-MDS could be manifested. However, in cases of lower grade astrocytomas and oligodendrogliomas in adults and astrocytomas and medulloblastomas in children, ≤80% of the patients may survive ≥5 years (35, 36, 37) and, therefore, may be at risk for development of either t-MDS or t-AML.

t-AML and t-MDS developed in patients treated with alkylating chemotherapeutic agents have been characterized as having deletions in the long arm of chromosomes 5 and/or 7 (29 , 38, 39, 40) . In addition, a 4-fold increase in the frequency of p53 mutations in t-AML compared with AML or MDS has been observed (41) . In this context, p53 mutations in human malignancies are frequently associated with exposure to chemical carcinogens (42) . Recent studies have demonstrated that the risk of t-AML in treated patients is modified by genetic polymorphisms, which alter levels of DNA damage and repair (43, 44, 45, 46) . Taken together, these results suggest that the formation of genomic damage and induction of mutations may play an important role in the etiology of t-AML in patients treated with alkylating chemotherapeutic agents.

Studies by Shering-Plough (47) have demonstrated that treatment of male and female rats with TMZ results in the induction of tumors in multiple tissues after administration of TMZ. The doses of TMZ used in those studies correspond to 12.5–100% of the dose given to patients (47) . Analysis of the reported organ specificity for carcinogenicity by TMZ administration shows that it is very similar to that of PCB (26 , 27) . These observations suggest that analysis of the mutagenic potential of TMZ is warranted.

The Big Blue Rat-2 cells were derived from a rat embryo cell line and carry stably integrated copies of the λ/lacI shuttle vector. This cell line has been used to investigate the mutagenicity of a number of alkylating agents (48, 49, 50) . This model system has a number of advantages, including ease of determining mutant frequency. In addition, because of the relatively small size of the lacI gene, it can be easily sequenced, and the mutation spectrum can be determined (49 , 50) .

In these studies, we have investigated the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. These studies demonstrate that treatment of Big Blue Rat-2 cells with TMZ results in a dose-dependent increase in DNA adduct formation and lacI mutant frequency. We interpret these results to suggest that treatment of patients with low-grade brain tumors with this agent may result in an increased risk for t-AML.

Materials and Methods

Materials

TMZ was provided by Developmental Therapeutics Program, National Cancer Institute (Bethesda, MD), The Big Blue Rat-2 cell line was purchased from Stratagene (La Jolla, CA). Supplies for mutation analysis were purchased from Stratagene. N7-MeG and O6-MedG were purchased from Chemsyn Science Laboratories (Lenexa, KS). O6-MeG was prepared previously (51) .

Cell Culture and Treatment

Big Blue Rat-2 cells were grown in 175 cm2 flasks containing 25 ml of Eagle’s minimum essential medium supplemented with 10% FCS and 50 μg/ml gentamicin. The cells were maintained and treated at 37°C in a humidified 5% CO2, 95% air atmosphere. For the treatments, TMZ was freshly dissolved in DMSO. TMZ was added directly to the culture medium to achieve the final treatment concentrations. After a 3-h treatment, the cells were washed with HBSS and either collected or fresh medium was added. For control treatments, the cells were treated with DMSO. For measurement of DNA adduct levels, the cells were collected after the treatment. For mutation analysis, the cells were collected 24 h after treatment. The cells were trypsinized and collected by centrifugation. The cellular pellets were quick frozen and stored at −80°C until DNA isolation.

Reaction of TMZ with DNA

Individual reactions, containing 500 μg of purified calf-thymus DNA in 100 mm triethanolamine buffer (pH 7.0) and 500 μm TMZ, were incubated at 37°C for various lengths of time. The individual reactions were stopped by precipitating the DNA with ethanol. The DNA was collected by centrifugation, and the pellet was dissolved in 15 mm sodium chloride and 1.5 mm sodium citrate pH 7.0 (0.1 × SSC).

Measurement of DNA Adducts

Isolation of DNA.

The DNA was isolated from the cellular pellets using a chloroform-isoamylalcohol extraction procedure. After initial isolation, the samples were incubated with a combination of pancreatic RNase A and T1 and T2 RNase followed by proteinase k. The DNA-containing solutions were subsequently extracted with chloroform-isoamylalcohol (24:1). The DNA samples were precipitated using sodium acetate and ethanol and collected by centrifugation. The DNA samples were dissolved in 0.1 × SSC buffer, and their concentration was determined from their absorbance at 260 nm.

DNA Hydrolysis Methods.

For quantification of O6-MeG, 100 μg of DNA from each sample were digested for 2 h at 37°C in 10 mm Tris (pH 7.5) and 1 μm MgCl2 with a mixture of pancreatic DNase I (15 units), snake venom phosphodiesterase (1.5 units), and alkaline phosphatase (0.65 units). After incubation, the samples were heated at 90°C for 1 min and then chilled. The hydrolysates were filtered with 0.2-μm centrifugal microfilters at 1300 × g.

For quantification of N7-MeG, 100 μg of DNA in 100 μl of 0.1 × SSC buffer were heated at 100°C for 30 min (52) . The samples were chilled in an ice bath, and 100 μl of cold 1 m HCl were added. The samples were centrifuged at 1300 × g, 0°C for 10 min to collect the DNA. The pellet was washed once with 100 μl of cold 1 m HCl and centrifuged as described above. Both supernatants were combined and adjusted to pH 6 with the addition of 4 m sodium acetate (pH 6.4) and concentrated NH4OH. The hydrolysates were filtered before prepurification.

Prepurification of N7-MeG and O6-MedG.

An HPLC-UV system consisting of a model 250 Perkin-Elmer solvent delivery system with a Perkin-Elmer LC 235 diode array detector was used (Cupertino, CA). A 5-μm C-18 reversed phase analytical column with column dimensions of 250 × 4.6 mm (Econosphere; Alltech Associates, Deerfield, IL) was used for the prepurification separations. Column temperature was set at 28°C with a Perkin-Elmer column oven. For prepurification of N7-MeG, the column was eluted with an isocratic mobile phase of 10 mm sodium acetate (pH 5.3) with 5% methanol. For prepurification of O6-MedG, the column was eluted with 10 mm sodium acetate (pH 5.3) containing 18% methanol. Fractions corresponding to the elution of N7-MeG and O6-MedG were collected and reduced in volume. The fractions containing O6-MedG were pooled and reduced to 90 μl using a speed-vac concentrator. Ten μl of 1 N HCl were added, and the solutions were heated at 62°C for 30 min to convert O6-MedG to O6-MeG.

HPLC-EC Detection.

The HPLC-EC system consisting of a model 580 ESA solvent delivery system with an SSI pulse dampener coupled to an ESA Coulochem II electrochemical detector with an ESA 5010 analytical cell was used (Chelmsford, MA). A 5-μm Econosphere column was used for the analytical separations. Column temperature was set at 30°C. The column was eluted with an isocratic mobile phase of 50 mm sodium acetate (pH 5.3) with 10% methanol for quantification of N7-MeG.

Electrode 1 was set at an oxidation potential of +600 mV. Electrode 2 was set at oxidation potentials of +850 mV for N7-MeG. Electrochemical response was digitized with a Nelson interface and analyzed using TurboChrom 4 software (Perkin-Elmer). Standard curve(s) was generated by measuring EC response after injection of standard solutions of N7-MeG over the concentration range of 0.05–1 pmol. Levels of adducts in the individual samples were determined by comparison with the standard curve (52) .

HPLC-FL Detection.

An HPLC-FL system consisting of a model 250 Perkin-Elmer solvent delivery system with a Perkin-Elmer LC-240 fluorescence detector was used. Excitation and emission wavelengths were set at 286 and 358 nm, respectively. A 10-μm strong cation exchange column with dimensions of 250 × 4.6 mm (Partisil; Alltech) was used for the HPLC-FL analysis. The column was eluted with an isocratic mobile phase of 110 mm ammonium phosphate (pH 2.0) for quantification of O6-MeG. Fluorescence response was digitized with a Nelson interface and analyzed using TurboChrom 4 software (Perkin-Elmer). Standard curve(s) was generated by measuring fluorescence response after injection of standard solutions of O6-MeG over the concentration range of 0.05–1 pmol. Levels of O6-MeG in the individual samples were determined by comparison with the standard curve.

Analysis of lacI Mutations

Genomic DNA Isolation.

Genomic DNA was isolated from the Big Blue Rat-2 cells using the Recover-ease genomic DNA isolation kit according to the manufacturer’s recommendation (Stratagene).

Packaging and Plating.

The λ bacteriophage shuttle vector was recovered from the genomic DNA by in vitro packaging using Transpack packaging extracts (Stratagene). Escherichia coli cells at a density of 0.5 A600 nm (SCS-8; Stratagene) were infected with the packaged DNA. The infected bacteria were mixed with top agarose containing 1.5 mg/ml X-gal and plated on 20 × 20 cm agar plaque trays. The total number of plaques was determined by counting duplicate plates of diluted aliquots of the infected bacteria. The total number of plaques per plate was extrapolated from the titer plates.

Sequencing.

Pure stocks of each mutant clone were made by reinfecting bacteria cells with isolated mutant bacteriophage at a low density. This procedure allowed for the isolation of a single lacI plaque from each original mutant plaque. The isolated mutant lacI DNA was amplified directly by PCR using plaque-forming unit Turbo DNA polymerase (Stratagene) and a Perkin-Elmer 2400 thermocycler. The following conditions were used for the amplification: 95°C for 5 min, followed by 30 cycles of 90°C for 20 s, 59°C for 30 s, 72°C for 40 s, and followed by a 7-min incubation at 72°C after the last cycle. The PCR products were purified with Wizard PCR Preps (Promega, Madison WI) and sequenced with a Big Dye Terminator cycle sequencing kit according to the manufacturer’s suggested procedure (Applied Biosystems, Foster City, CA) using a Perkin-Elmer 2400 thermocycler. Initially, a primer homologous to a 5′-untranscribed region of the lacI gene from −53 to −37 (5′-CCCGACACCATCGAATG-3′) was used to identify mutations in the first half of the gene where most of the mutations are found. When no mutations were found in this region of the gene, a second primer homologous to the lacI gene from 1208 to 1191 (5′-TCCGCTCACAATTCCACA-3′) in the 3′-untranslated region was used to sequence the later half of the gene (43) . Sequence reactions were run on an ABI Prism 377a or 3700 automated DNA sequencer at the Biomolecular Resource Center, University of California at San Francisco. Sequence data were analyzed with EditView (Applied Biosystems) and Blast-2 comparison analysis (National Center for Biotechnology Information).

Statistical Analysis.

Statistical analysis was performed using Sigma Stat v 2.03 (SPSS, Inc., Chicago, IL). Comparison of mutant frequencies was performed with a t test analysis. Ps < 0.05 were considered to be significant. Correlation of DNA adduct levels and TMZ treatment concentrations was performed using linear regression analysis. The association of O6-MedG levels with lacI mutant frequencies was evaluated with a Spearman rank correlation test. Comparison of the proportion of mutation types in the control and TMZ treatment groups was performed using a χ2 analysis with a α = 0.05. Comparison of individual mutation types in the control and TMZ treatment groups was performed using a Fisher exact test.

Results

To establish the length of treatment of Rat-2 cells with TMZ, the levels of N7-MeG and O6-MeG produced by incubation of calf thymus DNA for various lengths of time with 500 μm TMZ were quantified. As shown in Fig. 2⇓ , the levels of both of these adducts increased linearly with time ≤∼120 min. Between 120 and 180 min of incubation, the level of DNA alkylation plateaus. Comparison of the levels of O6-MeG/N7-MeG gives a alkylation product ratio of ≈0.1. On the basis of these results with DNA alkylation, we chose to treat Big Blue Rat-2 cells with TMZ for 3 h.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Formation of adducts in DNA incubated with 500 μm TMZ for various lengths of time at 37°C. The levels of N7-MeG (•–•–•) and O6-MeG (▪–▪–▪) are indicated.

Big Blue Rat-2 cells were treated with various concentrations of TMZ for 3 h. The levels of N7-MeG and O6-MeG in DNA produced by these treatments were quantified. As shown in Table 1⇓ , treatment of Big Blue Rat-2 cells with TMZ produced a dose-dependent increase in the level of both of these DNA adducts. These adducts were not observed in DNA isolated from the control treatment group. Linear regression analysis of the data showed a significant association between TMZ concentration and the level of both N7-MeG, R2 = 0.96, (P < 0.001) and O6-MeG, R2 = 0.91, (P < 0.001).

View this table:
  • View inline
  • View popup
Table 1

Levels of O6-MeG and N7-MeG in Big Blue Rat-2 cells after treatment with TMZ

Big Blue Rat-2 cells were treated with either 0, 0.5, or 1 mm TMZ and then collected 24 h after treatment for the analysis of lacI mutations. The results of these measurements are summarized in Table 2⇓ . The mean levels of lacI mutants in the control, 0.5 mm, and 1 mm TMZ treatment groups were 9.1 ± 2.9 × 10−5, 48.9 ± 12 × 10−5, and 89.7 ± 40.3 × 10−5, respectively. Comparison of the mutant frequencies demonstrates that the 0.5 and 1 mm TMZ treatments have increased the lacI mutant frequency by 5.3- and 9.8-fold, respectively. This increase in mutant frequency was significant for both the 0.5 mm (P < 0.001) and 1 mm TMZ (P < 0.003) treatment groups.

View this table:
  • View inline
  • View popup
Table 2

lacI mutant frequencies in Big Blue Rat-2 cells treated with TMZ

Sequence analysis of 21 lacI mutants from the 1 mm TMZ treatment group demonstrated that 19 of the 21 mutants were independent (Table 3)⇓ . Eighteen of these mutations (95%) were transition mutations at GC bp. Only one of the GC→AT transitions (6%) occurred at a CpG site (Table 3)⇓ . This lacI mutation spectrum observed in the TMZ treatment group is significantly different from the mutation spectrum observed in the control treatment group, where ≈80% of the GC→AT transitions occur at CpG sites (Table 3⇓ ; Refs. 49 and 50 ).

View this table:
  • View inline
  • View popup
Table 3

Summary of base substitutions found in spontaneous and TMZ-induced lacI mutations

Discussion

The purpose of these studies has been to measure the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with the chemotherapeutic agent TMZ. Treatment of these cells with TMZ produced a dose-dependent increase in the levels of O6-MeG and N7-MeG. The ratio of O6-MeG/N7-MeG alkylation products is ≈0.1 over the entire treatment dose range. This result suggests that significant repair of O6-MedG by AGT did not occur in Big Blue Rat-2 cells over the treatment interval investigated (51) .

Big Blue Rat-2 cells were treated with 0.125–2.5 mm TMZ for these studies. Pharmacokinetic analysis of the plasma levels of TMZ after a single treatment gives a area under the curve level of 17 μg h/ml (53) . This is equivalent to a TMZ concentration of 0.088 mm. A single course of therapy with TMZ corresponds to five daily treatments which would represent a cumulative exposure dose of 0.44 mm TMZ. Therefore, we believe that the concentrations of TMZ used in this study are representative of the concentrations achieved in patients during one course of multiday therapy.

In a preliminary study, we have measured the levels of O6-MeG formed in the liver, lung, and kidney of athymic rats 24 h after i.p. administration of 128 mg/kg TMZ. The levels of O6-MeG in the liver, lung, and kidney after this treatment are 3.6, 11.9, and 13.3 pmol/μmol DNA, respectively.4 These levels of DNA alkylation produced in vivo by treatment with 128 mg/kg TMZ are similar to the levels of O6-MeG produced by treatment of Big Blue Rat-2 cells with TMZ (Table 1)⇓ . For treatment of brain tumors, one treatment cycle with TMZ consists of 150–200 mg/m2 TMZ taken daily for 5 days (4, 5, 6) . In rats, this would correspond to a TMZ treatment dose of 28.8–38.4 mg/kg daily (54) . Over a 5-day period, the total dose of TMZ administered to rats would be 144–192 mg/kg. On the basis of these comparisons, we believe that the levels of O6-MeG produced by treatment of either Big Blue Rat-2 cells with 0.5–1 mm TMZ or athymic rats with 128 mg/kg TMZ are representative of the DNA adduct levels produced in patients after one treatment cycle with TMZ.

Treatment of Big Blue Rat-2 cells with 0.5 and 1 mm TMZ resulted in a 5.3–9.8-fold increase in lacI mutant frequency (Table 2)⇓ . This increase in mutant frequency is similar to what is observed after treatment of Big Blue Rat-2 cells with 1 mm methylnitrosourea (48) . There is a significant association between lacI mutant frequency and level of O6-MeG after TMZ administration (r = 0.88 and P < 0.001) as determined by the Spearman rank correlation test. Recent studies by Cai et al. (55) have demonstrated that treatment of Chinese hamster ovary cells with TMZ resulted in a dose-dependent increase in Hprt mutant frequency. The increase in Hprt mutant frequency after TMZ treatment was dependent on the cellular levels of AGT (55) . Taken together, these studies demonstrate that TMZ has significant mutagenic potential in the absence of AGT.

Sequence analysis of 21 lacI mutants from the 1 mm TMZ treatment group demonstrated that 94% of the GC→AT transitions occurred at non-CpG sites (Table 3)⇓ . This lacI mutation spectrum observed in the TMZ treatment group is significantly different from the mutation spectrum observed in a control treatment group analyzed previously where the GC→AT transitions occur principally at CpG sites (Table 3⇓ ; Refs. 49 and 50 ). If we assume that the spontaneous mutation spectrum in the previous study is representative of the spontaneous mutants in this study, we can evaluate whether the mutation spectrum of the TMZ treatment group is different from the control group. Proportion comparison of the individual mutations in the control and TMZ treatment groups using a χ2 test analysis shows that they are significantly different (P < 0.001). The proportions of the total transition and transversion mutations and GC→AT mutations and their frequency at CpG sites in the control and TMZ treatment groups were significantly different (P = 0.003 and 0.026), as determined by a Fisher exact test. Furthermore, because treatment with 1 mm TMZ increased the lacI mutation frequency by ≈10-fold, we are confident that the mutations sequenced are primarily from the treatment.

Since the initial observation by Loveless (56) , the miscoding properties of O6-alkylguanine derivatives have been extensively studied (57) . The formation of O6-MeG and induction of GC→AT transition mutations by TMZ treatment are consistent with these mutations being derived from O6-MeG. This interpretation is also consistent with the observation by Cai et al. (55) that Hprt mutant frequency induced by TMZ treatment was dependent on the cellular levels of AGT.

TMZ is a group member of methylating chemotherapeutic agents, which include PCB, DTIC, and STZ. Treatment with these agents results in the formation O6-MeG and N7-MeG in both animal models and patients (12, 13, 14, 15, 16, 17, 18, 19) . Several investigators (22 , 24 , 25) have demonstrated that treatment with PCB results in a dose-dependent increase in lacZ mutant frequency in the bone marrow. The similarity of PCB and TMZ in the adducts formed and their relative levels suggests that treatment of patients with TMZ will result in the formation of DNA adducts and mutations in their bone marrow. The measurement of DNA adduct levels (15, 16, 17) and HPRT mutation frequencies in lymphocytes (58, 59, 60) of patients treated with TMZ may act as a molecular surrogate for this process in bone marrow (61) .

Treatment of patients with regimens containing alkylating chemotherapeutic agents results in an increased risk for t-AML. Alkylating chemotherapeutic agent-induced t-AML and t-MDS are characterized by deletions in the long arms of chromosomes 5 and/or 7 (29 , 38, 39, 40) and an increase in frequency of p53 mutations (41) . The evidence presented suggests that the formation of DNA adducts and induction of mutations by TMZ treatment may initiate the processes leading to the induction of t-AML or t-MDS in treated patients. Because of the reduced lung and kidney toxicity of TMZ compared with nitrosourea-based therapy, there is a trend for the treatment of lower grade brain tumors with TMZ. We believe that in adults with anaplastic astrocytomas and oligodendrogliomas and in children with astrocytomas, treatment with TMZ coupled with increased survival may allow for manifestation of t-AML or t-MDS. As a consequence, we suggest that careful consideration of the use of TMZ in the treatment of these patients should be given.

Acknowledgments

We thank Dr. Donald Giannini for his assistance in the development of the methods for quantitation of N7-MeG and Drs. Joseph Wiemels and Victor Levin for their helpful suggestions during the preparation of this manuscript.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Supported in part by Grants ES09500 and CA80685.

  • ↵2 To whom requests for reprints should be addressed, at University of California, Box 0555, San Francisco, CA 94143-0555. Phone: (415) 476-4899; Fax: (415) 476-5799; E-mail: bodell{at}itsa.ucsf.edu

  • ↵3 The abbreviations used are: GBM, glioblastoma multiforme; PCB, procarbazine; HPLC, high-performance liquid chromatography; DTIC, dacarbazine, STZ, streptozotocin; AML, acute myeloid leukemia; t-AML, therapy-related acute myeloid leukemia; t-MDS, therapy-related myelodysplastic syndrome; TMZ, temozolomide; N7-MeG, N7-methylguanine; O6-MedG, O6-methyl-2-deoxyguanosine; O6-MeG, O6-methylguanine; AGT, O6-alkylguanine-DNA-alkyltransferase; Hprt, hypoxanthine guanine phosphoribosyltransferase.

  • ↵4 W. J. Bodell, N. W. Gaikwad, and T. Ozawa. DNA adduct levels in intracerebral human glioma xenografts and normal tissues of athymic rats treated with temozolomide, submitted for publication.

  • Received July 3, 2002.
  • Revision received February 12, 2003.
  • Accepted March 4, 2003.

References

  1. ↵
    Stevens M. F., Newlands E. S. From triazines and triazenes to temozolomoide. Eur. J. Cancer, 29A: 1045-1047, 1993.
    OpenUrlCrossRef
  2. ↵
    Newlands E. S., Stevens M. F., Wedge S. R., Wheelhouse R. T., Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev., 23: 35-61, 1977.
    OpenUrl
  3. ↵
    Newlands E. S., O’Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M., Illingworth R. D., Richards P. G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur. J. Cancer, 32A: 2236-2244, 1996.
  4. ↵
    Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Mutlicentre CRC phase II study of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother. Pharmacol., 40: 484-488, 1977.
    OpenUrl
  5. ↵
    Yung W. K., Albright R. E., Olson J., Fredericks R., Fink K., Prados M. D., Brada M., Spence A., Hohl R. J., Shapiro W., Glantz M., Greenberg H., Selker R. G., Vick N. A., Rampling R., Friedman H., Phillips P., Bruner J., Yue N., Osoba D., Zaknoen S., Levin V. A. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 83: 588-593, 2000.
    OpenUrlCrossRefPubMed
  6. ↵
    Yung W. K. A., Prados M. D., Yaya-Tur R., Rosenfeld S. S., Brada M., Friedman H. S., Albright R., Olson J., Chang S. M., O’Neill A. M., Friedman A. H., Bruner J., Yue N., Dugan M., Zaknoen S., Levin V. A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol., 17: 2762-2771, 1999.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Chinot O. L., Honore S., Dufour H., Barrie M., Figarella-Branger D., Muracciole X., Braguer D., Martin P. M., Grisoli F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol., 19: 2449-2455, 2001.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    van Den Bent M. J., Keime-Guibert F., Brandes A. A., Taphoorn M. J., Kros J. M., Eskens F. A., Carpentier A. F. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 57: 340-342, 2001.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Schold S. C., Jr., Kuhn J. G., Chang S. M., Bosik M. E., Robins H. I., Mehta M. P., Spence A. M., Fulton D., Fink K. L., Prados M. D. A phase I trial of 1, 3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. J. Neuro-Oncol., 2: 34-39, 2000.
    OpenUrl
  10. ↵
    Nicholson H. S., Krailo M., Ames M. M., Seibel N. L., Reid J. M., Liu-Mares W., Vezina L. G., Ettinger A. G., Reaman G. H. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J. Clin. Oncol., 16: 3037-3043, 1998.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Groves M. D., Puduvalli V. K., Hess K. R., Jaeckle K. A., Peterson P., Yung W. K., Levin V. A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol., 20: 1383-1388, 2002.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Bennett R. A., Pegg A. E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res., 41: 2786-2790, 1981.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Wiestler O. D., Kleihues P., Rice J. M., Ivankovic S. DNA methylation in maternal, fetal and neonatal rat tissues following perinatal administration of procarbazine. J. Cancer Res. Clin. Oncol., 108: 56-59, 1984.
    OpenUrlPubMed
  14. ↵
    Meer L., Janzer R. C., Kleihues P., Kolara G. F. In vivo metabolism and reaction with DNA of the cytostatic agent 5-(3, 3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC). Biochem. Pharmacol., 35: 3243-3247, 1986.
    OpenUrlCrossRefPubMed
  15. ↵
    Souliotis V. L., Kaila S., Boussiotis V. A., Pangalis G. A., Kyrtopoulos S. A. Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationship with dose and repair. Cancer Res., 50: 2759-2764, 1990.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    van Delft J. H. M., van den Ende A. M. C., Keizer H. J., Ouwerkerk J., Baan R. A. Determination of N7-methlyguanine in DNA of white blood cells from patients treated with dacarbazine. Carcinogenesis (Lond.), 13: 1257-1259, 1992.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Mustonen R., Forsti A., Hietanen P., Hemminki K. Measurement by 32P-postlabeling of 7-methylguanine levels in white blood cell DNA of healthy individuals and cancer patients treated with dacarbazine and procarbazine. Human data and method development for 7-alkylguanines. Carcinogenesis, 12: 1423-1431, 1991.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Fong L. Y. Y., Bevill R. F., Thurmon J. C., Magee P. N. DNA adduct dosimetery and DNA repair in rats and pigs given repeated doses of procarbazine under conditions of carcinogenicity and human cancer chemotherapy respectively. Carcinogenesis (Lond.), 13: 2153-2159, 1992.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Souliotis V. L., Valavanis C., Boussiotis V. A., Pangalis A., Kyrtopoulos S. A. Comparative study of the formation and repair of O6-methylguanine in humans and rodents treated with dacarbazine. Carcinogenesis (Lond.), 17: 725-732, 1996.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Meikrantz W., Bergom M. A., Memisoglu A., Samson L. O6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis (Lond.), 19: 369-372, 1998.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Lange H., Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol., 125: 156-165, 1999.
    OpenUrlCrossRefPubMed
  22. ↵
    Myhr B. C. Validation studies with Muta Mouse: a transgenic model for detecting mutations in vivo. Environ. Mol. Mutagen., 18: 308-315, 1991.
    OpenUrlPubMed
  23. ↵
    Schmezer P., Eckeryt C., Liegibel U. M. Tissue-specific induction of mutations by streptozotocin in vivo. Mutat. Res., 307: 495-499, 1994.
    OpenUrlPubMed
  24. ↵
    Plesta V., Valavanis C., van Delft J. H. M., Steenwinkel M-J. S. T., Kyrtopoulous S. A. DNA damage and mutagenesis induced by procarbazine in λlacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. Carcinogenesis, 18: 2191-2196, 1997.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Suzuki T., Uno Y., Idehara K., Baba T., Maniwa J., Ohkouchi A., Wang X., Hayashi M., Sofuni T., Tsuruoka M., Miyajima H., Kondo K. Procarbazine genotoxicity in the Muta Mouse: strong clastogenicity and organ-specific induction of lacZ mutations. Mutat. Res., 444: 269-281, 1999.
    OpenUrlPubMed
  26. ↵
    Weisburger E. K. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer (Phila.), 40: 1935-1949, 1977.
    OpenUrlPubMed
  27. ↵
    IARC. Procarbazine Hydrochloride. IARC Sci. Publ., 26: 311-339, 1981.
    OpenUrl
  28. ↵
    Hard C. G. Identification of a high frequency model for renal carcinoma by the induction of renal tumors in the mouse with a single dose of streptozotocin. Cancer Res., 45: 703-706, 1985.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Pedersen-Bjergaard J. Radiotherapy and chemotherapy induced myelodysplasia and acute myeloid leukemia. A review. Leuk. Res., 16: 61-65, 1992.
  30. ↵
    Ng A., Taylor G. M., Eden O. B. Treatment related leukemia–a clinical and scientific challenge. Cancer Treat. Rev., 26: 377-391, 2000.
    OpenUrlCrossRefPubMed
  31. ↵
    Cohen R. J., Wiernik P. H., Walker M. D. Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases. Cancer Treat. Rep., 60: 1257-1261, 1976.
    OpenUrlPubMed
  32. ↵
    Genot J-Y., Krulik M., Poisson M., Van Efferterre R., Renoux M., Audebert A. A., Canuel C., Smadja N., Debray J. Two cases of acute leukemia following treatment of malignant glioma. Cancer (Phila.), 52: 222-226, 1983.
    OpenUrlCrossRefPubMed
  33. ↵
    Perry J. R., Brown M. T., Gockerman J. P. Acute leukemia following treatment of malignant gliomas. J. Neuro-Oncol., 40: 39-46, 1998.
    OpenUrlCrossRefPubMed
  34. ↵
    Chandler K. L., Prados M. D., Malec M., Wilson C. B. Long-term survival in patients with glioblastoma multiforme. Neurosurgery, 32: 716-720, 1993.
    OpenUrlPubMed
  35. ↵
    Shaw E. G., Scheithauer B. W., Dinapoli R. P. Low-grade hemispheric astrocytomas Black P. M Loeffler J. S. eds. . Cancer of The Nervous System, 441-461, Blackwell Science Cambridge, MA 1997.
  36. ↵
    Cairncross J. G., Ueki K., Zlatescu M. C., Lisle D. K., Finkelstein D. M., Hammond R. R., Silver J. S., Stark P. C., Macdonald D. R., Ino Y., Ramsay D. A., Louis D. N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. (Bethesda), 90: 1473-1489, 1998.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Packer R. J., Sutton L. N., Elterman R., Lange B., Goldwein J., Nicholson H. S., Mulne L., Boyett J., D’Angio G., Wechsler-Jentzsch K., Reaman G., Cohen B. H., Bruce D. A., Rorke L. B., Molloy P., Ryan J., LaFond D., Evans A. E., Schut L. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU and vincristine chemotherapy. J. Neurosurg., 81: 690-698, 1994.
    OpenUrlPubMed
  38. ↵
    Le Beau M. M., Albain K. S., Larson R. A., Vardiman J. W., Davis E. M., Blough R. R., Golomb H. M., Rowley J. D. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no 5 and 7. J. Clin. Oncol., 4: 325-345, 1986.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Pedersen-Bjergaared J., Janssen J. W. G., Lyons J., Philip P., Bartram C. R. Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res., 48: 1812-1817, 1988.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Andersen M. K., Christiansen D. H., Kirchhoff M., Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer, 31: 33-41, 2001.
    OpenUrlCrossRefPubMed
  41. ↵
    Christiansen D. H., Andersen M. K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis. J. Clin. Oncol., 19: 1405-1413, 2001.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Hussain S. P., Harris C. C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res., 428: 23-32, 1999.
    OpenUrlCrossRefPubMed
  43. ↵
    Felix C. A., Hosler M. R., Provisor D., Salhany K., Sexsmith E. A., Slater D. J., Cheung. N. K., Winick N. J., Strauss E. A., Heyn R., Lange B. J., Malkin D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood, 87: 4376-4381, 1996.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Felix C. A., Walker A. H., Lange B. J., Williams T. M., Winick N. J., Cheung N. K. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA, 95: 13176-13181, 1998.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Larson R. A., Wang Y., Banerjee M., Wiemels J., Hartford C., Le Beau M. M., Smith M. T. Prevalence of the inactivating 609 C→T polymorphism in the NAD(P)H: quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94: 803-807, 1999.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Allan J. M., Wild C. P., Rollinsin S., Willert E. V., Moorman A. V., Dovey G. J., Roddam P. L., Roman E., Cartwright R. A., Morgan G. J. Poylmorphisms in glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukemia. Proc. Natl. Acad. Sci. USA, 98: 11592-11597, 2001.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Schering Plough. Temodar Product Information sheet, 1999.
  48. ↵
    Wyborski D. L., Malkhoysan S., Moores J., Perucho M., Short J. M. Development of a rat cell line containing stably integrated copies of a lambda/lacI shuttle vector. Mutat. Res., 334: 161-165, 1995.
    OpenUrlCrossRefPubMed
  49. ↵
    Zimmer D. M., Zhang P. R., Harbach P. R., Mayo J. K., Aaron C. S. Spontaneous and ethylnitrosourea-induced mutation fixation and molecular spectra at the lacI transgene in the Big Blue Rat-2 embryo cell line. Eniron. Mol. Mutagen., 28: 325-333, 1996.
    OpenUrl
  50. ↵
    Sprung C. N., Wang Y., Miller D. L., Giannini D. D., Dhananjaya N., Bodell W. J. Induction of lacI mutations in Big Blue Rat-2 cells treated with 1-(2-hydroxyethyl)-1-nitrosourea: a model system for the analysis of mutagenic potential of the hydroxyethyl adducts produced by 1, 3-bis (2-chloroethyl)-1-nitrosourea. Mutat. Res., 484: 77-86, 2001.
    OpenUrlPubMed
  51. ↵
    Bodell W. J., Rupniak H. T. R., Rasmussen J., Morgan W. F., Rosenblum M. L. Reduced level of DNA crosslinks and sister chromatid exchanges in 1, 3 bis (2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells. Cancer Res., 44: 3763-3767, 1984.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Ye Q., Bodell W. J. Detection of N7-(2-hydroxyethyl) guanine adducts in DNA and 9L cells treated with 1-(2-chloroethyl)-1-nitrosourea. J. Chromatogr. B, 694: 65-70, 1977.
    OpenUrl
  53. ↵
    Baker S. D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S. E., Dugan M., Cutler D., Batra V., Grochow L. B., Donehower R. C., Rowinsky E. K. Absorption, metabolism and excretion of 14C-Temozolomide after p.o. administration to patients with advanced cancer. Clin. Cancer Res., 5: 309-317, 1999.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Freireich E. J., Gehan E. A., Rall D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep., 50: 219-244, 1966.
    OpenUrlPubMed
  55. ↵
    Cai Y., Wu M. H., Xu-Welliver M., Pegg A. E., Ludeman S. M., Dolan M. E. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity in chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA-alkyltransferase. Cancer Res., 60: 5464-5469, 2000.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    Loveless A. Possible relevance of O6-alkylation of deoxyguanosine to mutagenicity of nitrosoamines and nitrosoamides. Nature (Lond.), 233: 206-208, 1969.
    OpenUrl
  57. ↵
    Singer B., Essigmann J. Site-specific mutagenesis: retrospective and prospective. Carcinogenesis (Lond.), 12: 949-955, 1991.
    OpenUrlFREE Full Text
  58. ↵
    Perera F. P., Motzer R. J., Tang D., Reed E., Parker R., Warburton D., O’Neill P., Albertini R., Bigbee W. L., Jensen R. H., Santella R., Tsai W-Y., Simon-Cereijido G., Randall C., Bosl G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res., 52: 3558-3565, 1992.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    Philip P. A., Souliotis V. L., Harris A. L., Salisbury A., Tates A. D., Mitchell K., van Delft J. H., Ganesan T. S., Kyrtopoulos S. A. Methyl DNA adducts. DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin. Cancer Res., 2: 303-310, 1996.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Kubota M., Lin Y. W., Hamahata K., Sawada M., Koishi S., Hirota H., Wakazono Y. Cancer chemotherapy and somatic cell mutation. Mutat. Res., 470: 93-102, 2000.
    OpenUrlCrossRefPubMed
  61. ↵
    Grant B. W., Trombley L. M., Hunter T. C., Nicklas J. A., O’Neill J. P., Albertini R. J. HPRT mutations in vivo in human CD 34+ hematopoietic stem cells. Mutat. Res., 431: 183-198, 1999.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 12 (6)
June 2003
Volume 12, Issue 6
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide
William J. Bodell, Nilesh W. Gaikwad, Douglas Miller and Mitchel S. Berger
Cancer Epidemiol Biomarkers Prev June 1 2003 (12) (6) 545-551;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide
William J. Bodell, Nilesh W. Gaikwad, Douglas Miller and Mitchel S. Berger
Cancer Epidemiol Biomarkers Prev June 1 2003 (12) (6) 545-551;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement